A narrative review: research progress of adjuvant intensive endocrine therapy for early breast cancer.

ABSTRACT:

Background and objective

Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR⁺/HER2^-) breast cancer (BC) is the most prevalent subtype of all BCs. The primary treatment modality is endocrine therapy (ET). Traditional adjuvant ET for early-stage breast cancer (EBC) has undergone extensive exploration and is relatively well-established. However, patients at high risk of recurrence may still experience early relapse, necessitating consideration of intensified adjuvant ET to reduce recurrence risk. The objective of this narrative review is to examine various strategies for intensifying adjuvant ET in EBC, thoroughly analyze key clinical studies, and summarize the most effective treatment approaches supported by current evidence-based med

SUBMITTER: Ye H 

PROVIDER: S-EPMC11341998 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature